Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADAMTS-like protein 5 (ADAMTSL5) is a secreted, N-glycosylated glycoprotein of the ADAMTS-like family found in the extracellular matrix and on cell surfaces[1][2][3]. It is characterized by a unique modular organization including an N-terminal thrombospondin type-1 repeat, a cysteine-rich and spacer module, and a C-terminal netrin-like (NTR) module. ADAMTSL5 binds to both fibrillin-1 and fibrillin-2, components of microfibrils in the extracellular matrix, implicating it in the regulation of microfibril function and ECM architecture[1][2][3]. It is broadly expressed in musculoskeletal and epithelial tissues. In the immune context, ADAMTSL5 is a melanocytic autoantigen presented by HLA-C*06:02, activating autoreactive T cells and contributing to psoriatic inflammation; its autoantibodies correlate with disease severity in psoriasis and psoriatic arthritis, highlighting a role as a potential biomarker[2]. No known drugs selectively target ADAMTSL5 and it is not currently considered a therapeutic target[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ADAMTS-like protein 5 (ADAMTSL5).